Diagnostic Services Areas of Expertise API, Chemical Development & Analytical Services Clinical Services Clinical Technologies Commercial Services Diagnostic Services Pharmaceutical Development Resource Type Search Search Topic Search Select topic 170 Genes AADx Adenocarcinoma Almac Almac Cancer DSA Analytical Analytics Angiogenesis Anti-Angiogenesis Anti-angiogenic Assay Assay Development Assay Validation Bevacizumab Bioinformatics Biolog Biologies Bioma Biomar Biomarke Biomarker Discovery Biopsy Biostatistics Breast Breast Cancer Brexit CDX CDx Development COL Dx Cancer Chemotherapy ClaraT Clinica Clinical Trial Assay Clinical Trial Enrichment Clinical Trial Supply Clinical Trials Clinical oncology Colon Colon Cancer Colorectal Cancer Companion Diagnostics Complex DDRD DNA DNA Damage Response DNA Microarray Damage Response Diagnostic Services Diagnostics Drug Development Drug Rescue EMT EXOME Early Efficacy Engines Esophogeal Expres FFPE Tissue Fact Gastric Cancer Gene Gene Expression Gene Targeting Genom Hallmarks of cancer Heterogeneity ILLUMNIA IVD Illumina Immune biology Ireland Liquid biopsy Lung Cancer MAPK Signaling Metastasis Metastatic Biology Metat Multiplex Signatures Mutation NEXT NGS NSCLC Next generation sequencing Northern Ireland Oncology Ovar Ovarian Ovarian Cancer Patient Stratification Patient Sub-Groups Personalized Medicine Platin Platinum therapy Precision Medicine PredictImmune Predictive Test Predictive assay Pro Prognosis Prognostic Prognostic Test Prospective Clinical Trials Prostate Prostate Cancer Quality & Regulatory RNA RUO Assay Radiolabeling Retrospective Clinical Trials STING SWOG Sample Management Sheet Statistical Models TP53 TP53 Assay TUMOR Tissue Collection Trans Trusight Tst Tumot Validation Select Resource type Almac Voice Article Blog Brochure Case study eBook Guide Newsletter Podcast Poster Presentation Publication Q&A Report Technical Publication Technical Sheet Video Webinar Whitepaper Patent Webinar Overcoming sample management challenges for clinical trials – The benefits of utilizing one end-to-end service provider Webinar Managing Biomarker/CDx Programs with Pharma – A Diagnostic Company’s Perspective Webinar Overcoming EU IVDR Challenges When Using Clinical Trial Assays to Accelerate Global CDx Trials Almac Voice Potential impact of IVDR on diagnostic testing in Europe – What are the implications for the pharmaceutical industry? Article Review of the Role of Biostatistics in the Life Cycle of Commercial Molecular Diagnostic Assays Article Twenty years of RNA research and diagnostic development… What have we learnt? Almac Voice A machine learning approach to detect FFPE artifacts leads to accurate estimation of tumor mutational burden from sequencing data without a matched normal Webinar Clinical Trial Assay Development for Precision Medicine: Insights from Pharma & Diagnostics Experts Webinar Identifying Personalized Therapeutic Vulnerabilities in Triple-Negative Breast Cancer Through Multigene Expression Signature Analysis Video Rising to the challenge of delivering precision medicines for chronic diseases Almac Voice The Important Role of Biostatistics in Clinical Trial Assay Validation: 4 Key Areas for Consideration Video Cambridge Science Festival 2022, Panel Discussion: “Can precision medicines transform healthcare for chronic diseases?” Webinar Biomarker Discovery from Gene Expression: Challenges & Solutions for Success Poster Impact of DNA Repair Deficiency Signature on Outcomes in Triple Negative Breast Cancer (TNBC) Patients Treated with AC Chemotherapy Technical Sheet RNA Exome White paper Technical Sheet RNA Exome Technical Specification Technical Sheet TP53 Performance Specification Technical Sheet TP53 Technical Specification Technical Sheet TST-170 Technical Specification (IUO) Report TST-170 Performance Specification Technical Sheet WES Technical Specification Whitepaper ClaraT Whitepaper Article Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology, published in the European Association of Urology Poster Association of a DNA Damage Response Deficiency (DDRD) Assay with Prognosis in Resected Esophageal and Gastric Adenocarcinoma Article View ColDX second Clinical Validation in the Journal of Clinical Oncology Article ColDx helps guide stage II colon cancer treatment- Hosted by Cancer Network Technical Sheet ClaraT Fact Sheet Case study PredictImmune partner with Almac Diagnostic Services for Bioinformatics & Software expertise Case study Almac Diagnostic Services and Analytics Engines Case Study Webinar Clinical Trial Assay & CDx Development in the Era of Precision Medicine – Planning for Success Webinar ClaraT Complimentary Webinar – Almac’s enhanced RNA-Seq reporting solution claraT – Simplifying complex biologies within the Hallmarks of Cancer Almac Voice The increasing uptake of RNA-Seq as the technology of choice in biomarker discovery Poster Poster Predictive assay for anti-angiogenic agents identifies a molecular subgroup of RAS wt mCRC with low efficacy of FOLFIRI plus bevacizumab Brochure Almac Diagnostic Services Capabilities Almac Voice Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial Technical Sheet Almac’s TruSight Oncology 500 ctDNA Factsheet Report Almac validated Illumina TruSight™ Tumor 170 cancer mutation panel. The assay is CLIA compliant for prospective clinical trial use, including Europe and the US Webinar Almac validate Illumina TruSight® Tumor 170 Assay Webinar Clinical Trial Assay Development and Validation – Strategies for Success Case study Almac Diagnostic Services and Analytics Engines Case Study Webinar Developing and Applying Biomarkers in Early Phase Clinical Trials Article World CB & CDx- An interview with Dr Jude O’Donnell Publication Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue Webinar The Realities of Running Next-Generation Sequencing Liquid Biopsy Panels in Clinical Trials Publication Identification and Validation of an Anthracycline / Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer Poster DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer Poster Identification of a novel breast cancer molecular subgroup associated with a deficiency in DNA-damage response Webinar Almac validate Illumina TruSight® Tumor 170 Assay Poster A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment Almac Voice The Almac Advantage – Post-Brexit Northern Ireland IVD Landscape Almac Voice Cancer gene expression signatures: The Rise and Fall…and Rise? Webinar Overcoming the Challenges of Taking RNA Biomarkers into Clinical Trials Webinar Accelerating Genomic Biomarker Translation Poster Platinum-based therapy selects for an angiogenic enriched tumor micro-environment in High Grade Serous Ovarian Cancer Poster Almac Diagnostic Services GU-ASCO Poster Publication Identification of a novel breast cancer molecular subgroup associated with a deficiency in DNA-damage response Article Platinum therapy resistance is associated with an enrichment of tumor angiogenesis in epithelial ovarian cancer Case study Almac Diagnostic Services and Analytics Engines Case Study Article Illumina TruSight Oncology 500 ctDNA Article Cancer gene expression signatures: The Rise and Fall…and Rise? Webinar Overcoming the Challenges of Taking RNA Biomarkers into Clinical Trials Webinar The Realities of Running Next-Generation Sequencing Liquid Biopsy Panels in Clinical Trials Webinar Almac’s enhanced RNA-Seq reporting solution claraT – Simplifying complex biologies within the Hallmarks of Cancer Almac Voice The increasing uptake of RNA-Seq as the technology of choice in biomarker discovery Webinar Almac validate Illumina TruSight® Tumor 170 Assay Webinar Optimizing Assays from FFPE for Biomarker Strategies Webinar An Integrated Approach to Biomarker Discovery Webinar NGS Panels – From Patient Selection to CDx Webinar Next Generation Sequencing in Companion Diagnostic Development Webinar Retrospective Sample Collection – Biomarker Discovery to Help Rescue your Drug Webinar Discovery, Development and Commercialization of Multiplex Diagnostic Services and Companion Diagnostic Services Webinar Developing and Applying Biomarkers in Early Phase Clinical Trials Poster Identification of a high-risk subgroup in primary prostate cancers presenting with targetable immune biology Poster The development and utilization of a novel DNA microarray platform for biomarker and target identification in advanced prostate cancer Poster Development of Expression Based Biomarkers in NSCLC: A Study of Intratumor Heterogeneity Using FFPE Tissue Poster DNA Damage Response Deficiency Assay predicts response to treatment in ovarian cancer Poster A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment Poster Association of a DNA Damage Response Deficiency (DDRD) Assay with Prognosis in Resected Esophageal and Gastric Adenocarcinoma Poster Impact of DNA Repair Deficiency Signature on Outcomes in Triple Negative Breast Cancer TNBC Patients Treated with AC Chemotherapy Poster Platinum-based therapy selects for an angiogenic enriched tumor micro-environment in High Grade Serous Ovarian Cancer Poster Development of a Pan-Cancer 15 Gene Expression Signature to Detect a Subgroup Driven by MAPK Signaling Poster Predictive assay for anti-angiogenic agents (AADx) identifies a molecular subgroup of RAS wt mCRC with low efficacy of FOLFIRI plus bevacizumab – analysis of the FIRE-3 (AIO KRK-0306) trial Publication Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy Publication Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients with Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance) Publication Development and Independent Validation of a Prognostic Assay for Stage II Colon Cancer Using Formalin-Fixed Paraffin-Embedded Tissue Publication Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer Publication Identification and Validation of an Anthracycline / Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer Publication Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology Almac Voice Almac Voice: An introductory guide to biomarkers, precision, personalized and stratified medicine Almac Voice NGS (Next Generation Sequencing) panels and patient tumor testing for stratified medicine Video Dr Stewart McWilliams – VP Quality and Regulatory Affairs Video Laboratories – Leeona Galligan, VP Commercial Operations Video Almac Diagnostic Services Corporate Video Webinar Diagnostic Solutions to enable translational research & biomarker-driven clinical trials Article Analytical validation of a prognostic prostate cancer gene expression assay using formalin fixed paraffin embedded tissue Article CDx, NGS and regulation: five perspectives from the Pistoia Alliance Webinar Clinical Trial Assay & CDx Development in the Era of Precision Medicine – Planning for Success Article Personalized Medicine from Concept to Clinical Use Make an Enquiry If you are interested in our Diagnostic Services, then please contact us Contact Us Meet the Experts Learn more about our experts in your discipline today Find out More
